COGT Cogent Biosciences, Inc.

$31.38▼ -1.88% Unknown Other Last sync: just now Syncing
Key Metrics & Fundamentals
Market Cap
$5.36B
P/E Ratio
–
Div Yield
–%
52W Range
6.88 - 43.73
% vs 50 MA
-8.54%
% vs 200 MA
5.37%
RSI-14
41.3
MACD Histogram
-0.1500
Beta (1Y vs SPY)
2.53
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Volume (M)
Financial Overview - Income Statement Quarterly
N/A

No financial data available. Click Refresh on the ticker to load latest fundamentals.

Social Sentiment
Avg -0.10 · 2 posts
list of all pre-revenue companies sorted by market capitalization.
r/stocks · Sep 24, 2025
The post expresses skepticism about companies like OKLO and COGT with no revenue or product, indicating a negative sentiment towards these investments.
negative -0.60
TradeATYR short puts on margin
r/wallstreetbets · Jul 16, 2025
The author references a past profitable strategy using COGT, indicating a positive view.
positive +0.40
AI Analysis
Generated May 28, 9:33 PM
Company Overview

Cogent Biosciences is a clinical-stage biotechnology company dedicated to developing precision therapies for genetically defined diseases. Their primary focus is on bezuclastinib, a selective KIT D816V inhibitor, currently in clinical trials for systemic mastocytosis and gastrointestinal stromal tumors. This specialized approach positions them in a high-potential, yet competitive, niche within the oncology and rare disease markets.

Bull Case
  • Potential of lead candidate bezuclastinib to address significant unmet needs in systemic mastocytosis and gastrointestinal stromal tumors.
  • Focus on precision medicine targeting specific genetic mutations, which can lead to highly effective and differentiated therapies.
  • Substantial market capitalization for a clinical-stage biotech, indicating strong investor confidence in its pipeline and future prospects.
  • Positive long-term technical trend, with the stock trading significantly above its 200-day moving average.
Bear Case
  • Significant clinical development risk inherent to a clinical-stage biotechnology company, with no approved products and high potential for trial failures.
  • Intense competition within the oncology and rare disease markets, potentially limiting market share even if products are approved.
  • High valuation of $6.05 billion for a pre-revenue company, making it highly sensitive to clinical setbacks or negative news.
  • Potential for future equity dilution to fund ongoing research and development, which could negatively impact shareholder value.
Recent Performance

COGT experienced a positive daily move of 2.5%, yet remains 19.1% below its 52-week high, suggesting a recent pullback from peak levels. While the stock is currently trading below its 50-day moving average by 4.1%, indicating some short-term weakness or consolidation, it maintains a robust long-term trend, sitting 15.9% above its 200-day moving average. The RSI of 47.1 is neutral, implying neither overbought nor oversold conditions, but the mixed moving average signals suggest a battle between short-term selling pressure and underlying long-term bullish momentum.

AI-generated analysis is for informational purposes only and does not constitute financial advice.

Not Financial Advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making any investment decisions. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙